作者: Burbano, Rommel Mario Rodríguez ; Montenegro, Raquel Carvalho ; Mesquita, Felipe Pantoja ; da Silva, Emerson Lucena ; Gomes, Bruna Puty Silva ; de Oliveira, Edivaldo Herculano Correa ; Pinto, Laine Celestino ; de Moares, Maria Elisabete Amaral ; de Souza, Pedro Filho Noronha

Gastric cancer (GC) is a common cancer worldwide. Therefore, searching for effective treatments is essential, and drug repositioning can be a promising strategy to find new potential drugs for GC therapy. For the first time, we sought to identify molecular alterations and validate new mechanisms related to Mebendazole (MBZ) treatment in GC cells through transcriptome analysis using microarray technology. Data revealed 1066 differentially expressed genes (DEGs), of which 345 (2.41 %) genes were upregulated, 721 (5.04 %) genes were downregulated, and 13,231 (92.54 %) genes remained unaltered after MBZ exposure. The overexpressed genes identified were CCL2, IL1A, and CDKN1A. In contrast, the H3C7, H3C11, and H1-5 were the top 3 underexpressed genes. Gene set enrichment analysis (GSEA) identified 8 pathways significantly overexpressed in the treated group (p < 0.05 and FDR<0.25). The validation of the expression of top desregulated genes by RT-qPCR confirmed the transcriptome results, where MBZ increased the CCL2, IL1A, and CDKN1A and reduced the H3C7, H3C11, and H1-5 transcript levels. Expression analysis in samples from TCGA databases correlated that the lower ILI1A and higher H3C11 and H1-5 gene expression are associated with decreased overall survival rates in patients with GC, indicating that MBZ treatment can improve the prognosis of patients. Thus, the data demonstrated that the drug MBZ alters the transcriptome of the AGP-01 lineage, mainly modulating the expression of histone proteins and inflammatory cytokines, indicating a possible epigenetic and immunological effect on tumor cells, these findings highlight new mechanisms of action related to MBZ treatment. Additional studies are still needed to better clarify the epigenetic and immune mechanism of MBZ in the therapy of GC.

2024-12-06·Journal of biomolecular structure & dynamics

Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer

Article

作者: Garg, Aakriti ; Karhana, Sonali ; Khan, Imran A. ; Khan, Mohd Ashif ; Bano, Aysha ; Reeta ; Nidhi

Emerging studies have reported the potential anticancer activity of benzimidazole-based anthelmintics (BBA) against lung cancer (LC). However, mechanism underlying the anticancer activity of BBA is unclear. Therefore, in the current study, network pharmacology and molecular docking-based approach were used to explore the potential molecular mechanism for the treatment of LC. The potential targets for BBA were obtained from multiple databases including SwissTargetPrediction, Drug Bank, Therapeutic Target Database, and Comparative Toxicogenomics Database while LC targets were collected from DisGeNet gene discovery platform, Integrated Genomic Database of NSCLC, Catalogue of Somatic Mutations in Cancer and Online Mendelian Inheritance in Man database. Protein-protein interaction (PPI) diagram of common targets was constructed using STRING online platform. Topological analysis was performed using Cytoscape and gene enrichment analysis was conducted using FunRich software. Highest degree targets were then confirmed using molecular docking and molecular dynamics simulations. The BBA were prioritized according to their S scores, with ricobendazole ranking highest followed by flubendazole, fenbendazole, mebendazole, triclabendazole, albendazole, oxibendazole, parbendazole, thiabendazole and oxfendazole. The potential targets of BBA identified using topological analysis and molecular docking were found to be CCND1 (cyclin D1), EGFR (Epidermal Growth Factor Receptor), ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2/CD340), PTGS2 (Prostaglandin-endoperoxide synthase 2), and SRC (Proto-oncogene tyrosine-protein kinase). Furthermore, molecular dynamics confirmed that CCND1 and EGFR are the potential targets of ricobendazole for the treatment of LC. BBA can be further explored as a therapeutic strategy for the treatment of lung cancer under in vitro and in vivo studies.Communicated by Ramaswamy H. Sarma.

2024-11-26·AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Diversity and Prevalence of Helminths and Protozoa Among Pregnant Women in Tropical Ecuador: Implications for Chemotherapy

Article

作者: Contreras, Jesse ; Calvopina, Manuel ; Cevallos, William ; Levy, Karen ; Lee, Gwenyth ; Eisenberg, Joseph N. S.

Deworming for pregnant women using a single dose of albendazole or mebendazole is recommended by the WHO in areas where the baseline prevalence of hookworm and/or trichuriasis is >20%. However, other helminths and protozoa infecting pregnant women are not affected by these drugs and dosages. To assess the prevalence and diversity of intestinal helminth and protozoan infections, we analyzed stool samples from pregnant women recently enrolled into a birth cohort, along a rural-urban gradient in northern coastal Ecuador from 2019 to 2022. Participants provided a stool sample in their third trimester (n = 444). Samples were concentrated by the Ritchie method and observed microscopically for the detection of cysts, eggs, and larvae. The overall prevalence of infection with one or more parasites was 69% (95% CI: 67–74%), ranging from 52% in urban participants to 76% in rural participants (percentile rank = 1.39, 95% CI: 1.07–1.87). This differential between urban and rural communities persisted when data were disaggregated into helminth and protozoan infections (prevalence = 19% and 46%, respectively, in urban participants compared with 42% and 58% among rural participants). The most prevalent helminth was Ascaris lumbricoides (27%), followed by Trichuris trichiura (13%) and hookworm (7.4%). Hymenolepis nana, Strongyloides stercoralis, and Enterobius vermicularis were also observed. Six protozoan pathogens were detected, including Entamoeba histolytica/dispar (23%), Giardia intestinalis (5%), and Balantidium coli, along with nine protozoa that are nonpathogenic or of debated pathogenicity. The high infection burden and diversity of intestinal parasites found in this study highlight a need to revise strategies for preventing and treating intestinal parasitic infections in pregnant women.

项与甲苯咪唑相关的新闻（医药）

2024-02-14

·Science Daily

Controlling root growth direction could help save crops and mitigate climate change

Scientists have determined how the well-known plant hormone ethylene is crucial in controlling the angle at which roots grow. The findings can be used to engineer plants and crops that withstand the environmental stresses of climate change and drought, and perhaps to create plants that remove carbon dioxide from the atmosphere and store it deep underground to help mitigate climate change. Above ground, plants stretch toward the sun. Below ground, plants tunnel through the earth. As roots soak up water and nutrients from surrounding soil, they grow and stretch to develop distinct root system architectures. The root system architecture determines whether roots remain in the shallow soil layers or grow steeper and reach deeper soil layers. Root systems are central to plant survival and productivity, determining the plant's access to nutrients and water and, therefore, the plant's ability to withstand nutrient depletion and extreme weather like drought. Now, Salk scientists have determined how a well-known plant hormone is crucial in controlling the angle at which roots grow. The study, published in Cell Reports on February 13, 2024, is the first time the hormone, called ethylene, has been shown to be involved in regulating lateral root angles that shape root systems -- making the findings a revelation for plant scientists optimizing root systems. Researchers in Salk's Harnessing Plants Initiative now plan to target the ethylene signaling pathway in their efforts to engineer plants and crops that can withstand the environmental stresses of climate change and drought, as well as removecarbon dioxide from the atmosphere and store it deep underground to help mitigate climate change. "Deep roots lead to more durable carbon storage in the soil and can make plants more resistant to drought, so the ability to control how deep roots grow is really exciting for scientists looking to engineer better root systems," says senior author Wolfgang Busch, professor, executive director of the Harnessing Plants Initiative, and Hess Chair in Plant Science at Salk. "We're especially excited that the pathway we found is conserved across many types of plants, meaning our findings can be widely applied to optimize root architecture in all land plants, including food, feed, and fuel crops." Environmental factors -- like average rainfall or abundance of certain nutrients -- can influence the shape of a plant's root system. The angle at which roots grow produces different results in overall root architecture, with horizontal root angles creating a shallower root system and vertical root angles creating a deeper root system. But scientists did not understand clearly how these root angles were being determined on a molecular level. Plant hormones like auxin and cytokinin have been connected to the angle of root growth in the past, but the mechanisms of that connection have remained poorly understood. In searching for molecules and pathways that were involved in setting the angle of root growth, the team genetically screened Arabidopsis thaliana -- a small flowering weed in the mustard family -- for root system changes in response to thousands of molecules. "We noticed this molecule called mebendazole was causing the roots to grow more horizontally," says first author Wenrong He, a former postdoctoral researcher in Busch's lab. "When we looked for what target proteins or pathways mebendazole was interacting with to have this effect, we discovered it was ethylene signaling -- and ethylene playing such an essential role in root system architecture was really intriguing." The team observed that genes throughout the ethylene signaling pathway were activated in response to mebendazole, and, in turn, the pathway was carrying out the resulting changes in root growth. Biochemical investigation of this relationship revealed that mebendazole inhibits the activity of a protein kinase called CTR1. This enzyme negatively regulates ethylene signaling, in turn promoting a shallow root system. "Since ethylene signaling is a widely conserved process in land plants, targeting the ethylene pathway is a very promising technique for root system engineering," says Busch. "Hopefully, now we'll be able to use this tool to make crop species more resilient, and to create Salk Ideal Plants® that sequester more carbon underground to assist in the fight against climate change." The newfound implication of ethylene in root system architecture inspires new questions, including whether another molecule exists that -- unlike mebendazole -- makes root systems deeper, or if there are specific genes in the already well-cataloged ethylene signaling pathway that can be targeted most effectively to promote deeper roots in crops and Salk Ideal Plants. Other authors include Hai An Truong, Ling Zhang, Min Cao, and Kaizhen Zhong of Salk; Neal Arakawa of UC San Diego; Yao Xiao of the Scripps Research Institute; and Yingnan Hou of UC Riverside and Shanghai Jiao Tong University in China. The work was supported by Salk's Harnessing Plants Initiative, a Salk Women & Science Special Award, a Pioneer Fund Postdoctoral Scholar Award, the National Institutes of Health (NIH-NCI CCSG: P30 CA01495, NIH-NIA San Diego Nathan Shock Center P30 AG068635), Chapman Foundation, and Helmsley Charitable Trust.

2023-10-20

·Johnson & Johnson

Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model

Chicago, Illinois (October 20, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today promising data from a Phase 2a human challenge study evaluating JNJ-1802, a first-in-class oral antiviral in development for the prevention of dengue. The data showed that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo, and is safe and well-tolerated. The data were announced at the American Society of Tropical Medicine & Hygiene Annual Meeting in Chicago, Illinois.JNJ-1802 is the first antiviral to show such activity in humans during a clinical trial. The compound has advanced to a community-based field study to establish efficacy against circulating dengue serotypes in a real-world setting. The study is being conducted in 30+ sites in 10 countries, including Philippines, Thailand, Peru, Brazil and Colombia.“Climate change threatens to put more people at risk of dengue, yet the world lacks the necessary tools to combat this significant health challenge,” said Ruxandra Draghia-Akli, M.D., Ph.D., Global Head, Global Public Health R&D at Janssen Research & Development, LLC. “For over a decade, we have been committed to following the science to bring forward new solutions for dengue and this new data is an encouraging step forward to addressing the expanding impact of climate change on human health.”The two-center, randomized, double-blind, placebo-controlled human challenge study evaluated the antiviral activity, safety and pharmacokinetics of different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults. All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5. All participants were monitored over 85 days. The study found dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.“The promising results of JNJ-1802 to date offer the hope that science will be able to deliver against this threat as more and more communities are impacted worldwide,” said Marnix Van Loock, Ph.D., Lead for Emerging Pathogens, Global Public Health R&D at Janssen Pharmaceutica NV. “Dengue requires global action, and we are proud to collaborate alongside partners around the world in advancing the development of this compound to its next phase.”This study follows data published in Nature in March 2023, which showed that JNJ-1802 provides strong protection against dengue in non-human primates and mice, and a Phase 1 first-in-human clinical study showing that the antiviral was safe and well-tolerated.Janssen thanks its supporting partners including the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Clinical Research (DCR and Office of Clinical Research Policy and Regulatory Operations (OCRPRO) for their collaboration in conducting this trial.A New Tool to Fight a Growing ThreatThe development of a dengue antiviral is critically important to global health. Over half the world’s population currently lives in areas where dengue is endemic. Dengue fever impacts at least 400 million annually, sickening an estimated 100 million and killing thousands, with more going undiagnosed or misdiagnosed.Changes in climate are exacerbating the crisis, lengthening the infection season and allowing the mosquito that carries the virus to spread beyond its native regions. In 2023, countries like Bolivia, Peru and Bangladesh have already reported some of their worst outbreaks on record, and countries like the U.S., Spain and France are seeing a rise of locally acquired cases for the first time.Research and development (R&D) against dengue has proven challenging due to four globally circulating serotypes and there are currently no therapeutics and only two licensed vaccines limitedly available. Investment in antivirals, which do not require cold chain and can induce immunity in just days, is sorely needed to diversify the prevention toolbox to slow down outbreaks and limit epidemic-levels of cases.Johnson & Johnson’s Commitment to DengueJohnson & Johnson has been investing in dengue R&D for over a decade. The Company is also collaborating closely with academic partners to bolster local R&D. In June 2022, Johnson & Johnson launched its Satellite Center for Global Health Discovery at Duke-NUS in Singapore, which is focused on accelerating early-stage discovery research to address the growing challenge of flaviviruses, including dengue.These efforts are part of Johnson & Johnson’s more than 15-year legacy working to address the burden of neglected tropical diseases (NTDs), a group of about 20 communicable diseases that together affect more than 1.7 billion people in 149 countries around the world. In 2022, the Company joined the global community to endorse the Kigali Declaration on Neglected Tropical Diseases, pledging to continue to donate up to 200 million doses annually of mebendazole through 2025 to tackle intestinal worms and advance novel R&D programs to discover new medications needed to beat leprosy and dengue.You can learn more about our efforts to beat NTDs, including dengue, by visiting JNJ.com/NTDs.  About the Janssen Pharmaceutical Companies of Johnson & JohnsonAt Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.Learn more at www.janssen.com. Follow us at @JanssenUS and @JanssenGlobal. Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/. Cautions Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding dengue fever, flavivirus and neglected tropical diseases. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Pharmaceutica NV and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Pharmaceutica NV nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

临床2期疫苗临床结果临床1期

2023-09-15

·蒲公英Ouryao

再见，杨森制药！

转自：蒲公英Ouryao 综合：无忧9月14日，强生公司宣布品牌更新，将旗下医疗科技和制药两大业务整合至强生（Johnson&Johnson）名下。其中，公司制药部门杨森将更名为强生创新制药，医疗科技部门则保持不变。136年历史上最大的一次拆分9月14日，强生公司宣布品牌更新，将旗下医疗科技和制药两大业务整合至强生（Johnson&Johnson）名下。其中，公司制药部门杨森将更名为强生创新制药，医疗科技部门则保持不变。此次分拆是强生136年历史上最大的一次改组，预计将在明年完成。强生创新制药（Johnson&Johnson Innovative Medicine）专注于肿瘤、免疫、神经、心血管、肺动脉高压和视网膜等领域，以应对当今时代最复杂的疾病，并为未来开发前沿药物。今年1月24日，强生发布的2022财年最新数据显示，强生营收 949.4亿美元，其中制药业务营收525.6亿美元；拆分完成后，对于“新强生”，在今年初的JPM大会上，强生新任首席执行官Joaquin Duato表示，到2025年整体业务目标是达成800亿美元。为了实现这一目标，强生计划到2025年为现有13种重磅产品提交36份新适应症申请，这些产品将是到2025年业绩增长的主要动力。制药界奇才杨森1926年，保罗·杨森出生于比利时弗拉芒语区的小镇特恩哈特；1951年，保罗·杨森在根特大学完成临床培训，并成功获得医学博士学位。Perdolan：同年，保罗·杨森依靠求学期间获得的药理学知识，他以常见的德国止痛剂作为参照，结合乙酰氨基酚、阿司匹林和咖啡因研制出一种新产品Perdolan，后来这款产品成为了比利时最广泛使用的止痛剂之一。异丙胺：1954年，保罗·杨森在实验室成功制成了异丙胺——一种可抑制胃肠道平滑肌痉挛，并阻断胃液分泌的长效抗胆碱能药物。这一产品的生产许可随即被卖给了史克必成（2000年，史克必成与葛兰素威廉合并成为葛兰素史克），并为保罗·杨森带来了维持实验室运行的重要资金。在保罗·杨森的领导下，公司开发出一系列产品： 1956年，他主持开发了哌替啶的类似物，用于治疗腹泻的地芬诺酯（R1132），这个药物甚至进入了太空，在阿波罗计划中使用； 1966年，左旋咪唑（R12564），抗蠕虫药； 1967年，咪康唑（R14889），抗霉菌药； 1968年，甲苯咪唑（R17635），抗蠕虫药； 1969年，止泻药洛哌丁胺（R18553）（易蒙停）研制成功。它能高效抑制肠道运动，且无法穿越血脑屏障，后成为杨森最著名的药品之一； 1969年，抑霉唑（R23979），抗霉菌药物； 1974年，舒芬太尼（R30730），镇痛药； 1975年，丙环唑（R35432）（R49362），抗真菌药； 1976年，酮康唑（R41400），抗真菌药； 1984年，利培酮（R64766），精神安定药…… 在保罗·杨森博士的领导下，杨森制药分部壮大，一跃而成为世界知名的制药大公司，开发了100，000种以R开头编号的化合物，其中有80种已被作为人用、动物用和植物用药品开发；四个药物被列入世界卫生组织的基本药物目录！这绝对是一个世界纪录。他和他的团队开发的大多数药物为人类医学发展做出了贡献，被用来治疗真菌和寄生虫感染疾病，精神疾病，心血管疾病，过敏和胃肠道疾病。西安杨森，制药人的黄埔军校1976年，杨森博士在西安参观兵马俑时，发现泥土和空气中霉菌的腐蚀，正加速秦始皇兵马俑的颜色褪去后，向西安市捐赠一批抗真菌剂，来保护这些文物。自此，杨森与中国医药的命运齿轮开始转动... 1985年，美国强生子公司比利时杨森与中方四家制药公司（陕西省医药总公司、陕西省汉江药业股份有限公司、中国医药工业公司、中国医药对外贸易总公司）联合投资成立西安杨森。作为中国最大的合资制药企业、美国强生公司在华最大的子公司，西安杨森生产和销售涉及胃肠病学、神经精神学、变态反应学、疼痛管理学、抗感染、生物制剂和肿瘤等领域的高质量药品。除此多外西安杨森被认为与一般意义上的外资制药公司不同之处在于，它大规模系统地培育了中国第一代真正意义上的医药代表，将西方先进的学术推广等方式带入中国医药行业，大幅提高了国内临床医生对药物的认知水平。不仅如此，几乎所有在西安杨森供职过的人对其内部培训和职业成长计划都评价颇高。西安杨森的每名员工平均每年可以接受100小时有针对性的系统培训，其中10%的员工有机会接受海外培训。一个细节是，在上世纪80年代的西安杨森，每个人都被要求走上讲台进行3~15分钟不等的主题演讲，这种具有鲜明美国元素的训练方式，成就了此后活跃于中国医药领域最优秀的一批职业经理人。西安杨森被一致誉为业内的“黄埔军校”，曾在中国医药发展的历史上留下不可磨灭，浓墨重彩的一笔。参考：企业公告医学论坛网新康界

财报

100 项与甲苯咪唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00368	甲苯咪唑	P02CA01	DB00643

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
蛔虫病	美国	Janssen Pharmaceuticals, Inc.	1974-06-28
蛲虫病	美国	Janssen Pharmaceuticals, Inc.	1974-06-28
钩虫感染	美国	Janssen Pharmaceuticals, Inc.	1974-06-28
鞭虫病	美国	Janssen Pharmaceuticals, Inc.	1974-06-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
蠕虫病	临床3期	埃塞俄比亚	Janssen Research & Development LLC	2014-12-01
蠕虫病	临床3期	卢旺达	Janssen Research & Development LLC	2014-12-01
寄生虫病	临床3期	坦桑尼亚	Johnson & Johnson Pharmaceutical Research & Development LLC	2010-02-01
贫血	临床3期	巴基斯坦	Johns Hopkins Bloomberg School of Public Health	2004-04-01
脑干胶质瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22
弥漫内生性脑桥神经胶质瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22
多形性胶质母细胞瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22
神经胶质肉瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22
高级别胶质瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22
低级神经胶质瘤	临床2期	美国	Janssen Pharmaceuticals, Inc.	2013-10-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CTRI/2018/01/011542 (BELOB, ASCO2022) 人工标引	临床2期	复发性胶质母细胞瘤	-	lomustine+Mebendazole	襯襯膚壓壓憲鏇鏇蓋鑰(獵糧艱願餘憲願蓋艱構) = 簾衊壓艱遞襯鹽遞鏇膚製膚窪遞願餘淵鹹夢醖 (鹽艱廠膚憲醖淵積願繭, 29.6 ~ 59.2) 更多	不佳	2022-06-02
				temozolomide+Mebendazole	襯襯膚壓壓憲鏇鏇蓋鑰(獵糧艱願餘憲願蓋艱構) = 餘醖積顧餘夢艱憲願積製膚窪遞願餘淵鹹夢醖 (鹽艱廠膚憲醖淵積願繭, 22.3 ~ 51) 更多
NCT03925662 (Pubmed \| Life Sci) 人工标引	临床3期	转移性结直肠癌	40	Mebendazole + bevacizumab + FOLFOX4	積積遞鏇齋構範觸衊窪(艱觸構廠網遞顧願築積): P-Value = 0.063 更多	积极	2022-04-03
				Bevacizumab + FOLFOX4 + placebo
NCT03995680 (CHEW_MEB_PEMBA, CTgov)	临床2期	钩虫感染	397	Mebendazole (Chewable Tablet of Mebendazole)	鑰遞鬱膚醖積築鑰廠選(蓋築鹽鑰餘夢夢餘襯顧) = 觸獵願憲衊獵壓獵構衊憲艱蓋夢積構蓋繭觸繭 (衊鏇範鹽膚鹽壓衊積鬱, 艱憲廠廠構選襯餘蓋簾 ~ 夢膚構構夢獵壓淵繭夢) 更多	-	2020-07-20
				Mebendazole (Swallowable Tablet of Mebendazole)	鑰遞鬱膚醖積築鑰廠選(蓋築鹽鑰餘夢夢餘襯顧) = 餘鏇獵願遞繭繭窪餘鑰憲艱蓋夢積構蓋繭觸繭 (衊鏇範鹽膚鹽壓衊積鬱, 餘簾遞積鑰憲願製鬱鹹 ~ 襯顧積網鑰鏇夢鑰衊窪) 更多
NCT03245398 (CTgov)	临床4期	钩虫感染	186	one of the two regimens of mebendazole (Single Dose of Mebendazole)	繭願淵願窪鏇築膚鹽鏇(觸襯繭簾繭糧鹹廠築獵) = 餘壓窪鬱鏇夢觸壓願願遞餘廠齋獵顧壓衊齋夢 (積獵鹹簾願夢壓艱淵齋, 選憲襯艱夢簾艱襯醖築 ~ 艱選醖艱餘獵餘鬱顧製)	-	2019-06-17
				one of the two regimens of mebendazole (Multiple Dose of Mebendazole)	繭願淵願窪鏇築膚鹽鏇(觸襯繭簾繭糧鹹廠築獵) = 築鹹糧顧衊繭壓淵糧淵遞餘廠齋獵顧壓衊齋夢 (積獵鹹簾願夢壓艱淵齋, 範構襯膚鏇繭築製壓鹹 ~ 衊繭廠艱夢餘遞鑰餘艱)
NCT03245398 (Pubmed) 人工标引	临床4期	钩虫感染	185	Single dose mebendazole	壓憲選餘淵餘獵鑰糧選(艱構蓋淵構壓蓋遞製簾) = 鏇襯窪鏇範鬱醖壓鹹鹽廠醖觸積願獵廠構鹹鹹 (鑰廠衊鑰憲襯鹽窪衊蓋 ) 更多	积极	2018-07-01
				Multiple dose mebendazole	壓憲選餘淵餘獵鑰糧選(艱構蓋淵構壓蓋遞製簾) = 構廠齋獵夢簾範醖網獵廠醖觸積願獵廠構鹹鹹 (鑰廠衊鑰憲襯鹽窪衊蓋 ) 更多
NCT02034162 (CTgov)	临床3期	蠕虫病	295	placebo (Double-blind Placebo)	顧鹹餘遞餘簾選醖鹽壓(鑰蓋鹹夢淵顧選鹽繭鹹) = 餘夢觸網獵積齋膚積範顧顧鹹製獵窪夢壓繭淵 (鹽蓋壓鏇蓋獵簾鏇衊範, 艱範築鏇願壓觸膚齋壓 ~ 築蓋窪壓鹽鹹觸衊蓋網) 更多	-	2016-11-04
				Mebendazole (Double-blind Mebendazole 500 mg)	顧鹹餘遞餘簾選醖鹽壓(鑰蓋鹹夢淵顧選鹽繭鹹) = 衊廠窪鬱構顧淵餘壓壓顧顧鹹製獵窪夢壓繭淵 (鹽蓋壓鏇蓋獵簾鏇衊範, 鏇願繭遞鬱築膚獵鹽顧 ~ 鹹醖醖簾鹹鏇夢鬱齋選) 更多
NCT01379326 \| NCT01087099 (Pubmed \| PLoS Negl Trop Dis) 人工标引	临床4期	蠕虫病	250	Mebendazole 500 mg	膚齋構淵醖醖衊醖糧顧(憲鏇積鏇簾遞鹽齋願遞) = 簾構蓋鹽廠齋簾遞廠築鑰獵憲構網觸選憲觸遞 (襯齋願餘鹽鏇鹹憲簾簾, 95.8 ~ 99.5) 更多	积极	2014-10-01
				Albendazole 400 mg	膚齋構淵醖醖衊醖糧顧(憲鏇積鏇簾遞鹽齋願遞) = 顧艱鏇糧鹹憲廠壓壓顧鑰獵憲構網觸選憲觸遞 (襯齋願餘鹽鏇鹹憲簾簾, 99.0 ~ 100) 更多
NCT01350271 (CTgov)	临床3期	蠕虫病	214	Placebo (Placebo)	願願鏇襯製構遞壓齋選(選衊衊衊觸蓋艱鑰憲範) = 構簾襯蓋夢窪淵鏇選糧繭醖範壓繭憲選範遞憲 (蓋醖窪鹽願簾憲醖積廠, 製餘網襯蓋鹹壓選積製 ~ 齋淵窪餘窪齋顧遞簾齋) 更多	-	2013-04-22
				Mebendazole polymorph A (Mebendazole Polymorph A and C 500 mg)	願願鏇襯製構遞壓齋選(選衊衊衊觸蓋艱鑰憲範) = 憲醖廠願齋餘積糧網憲繭醖範壓繭憲選範遞憲 (蓋醖窪鹽願簾憲醖積廠, 襯膚餘鬱夢簾膚淵鑰襯 ~ 選蓋淵膚餘衊糧醖憲夢) 更多
ERS2012 人工标引	N/A	持续性哮喘 total IgE \| Ascaris-specific IgE	24	Mebendazole	淵齋簾鏇憲鹽蓋鑰繭觸(鏇願選願積顧願夢選鑰) = 鬱範積膚齋範鏇築蓋獵窪獵獵選願觸簾鹹願願 (壓壓廠觸願遞鏇構鑰遞 ) 更多	积极	2012-09-01
NCT00116493 (Pubmed \| J Nutr)	临床3期	-	462	Iron+folic acid	夢衊繭遞鹽顧糧鏇膚醖(觸鹽餘醖網遞淵繭網膚) = 網艱艱鏇網壓夢衊襯膚憲願鹹糧廠觸廠願積網 (選遞觸憲淵壓觸願範顧 )	-	2009-08-01